Clinical trial
Efficacy and Safety of Switching to Vemliver (Tenofovir Alafenamide) From Entecavir in Chronic Hepatitis B: A Multi-Center, Phase IV, Open-Label, Randomized, Active-Controlled, Non-Inferiority Trial.
NCT06000657 is registered in ClinicalTrials.gov with Daewoong Pharmaceutical Co. LTD. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Switching to Vemliver (Tenofovir Alafenamide) From Entecavir in Chronic Hepatitis B: A Multi-Center, Phase IV, Open-Label, Randomized, Active-Controlled, Non-Inferiority Trial.
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- August 28, 2023
- Completion date
- February 3, 2025
- Enrollment
- 196 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.